DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07014709

IPMN-GLP1RA

Not yet recruiting

Impact of GLP-1 Receptor Agonists on Patients With IPMN

Impact of GLP-1 Receptor Agonists on Patients With Intraductal Papillary Mucinous Neoplasms: A Retrospective Multicentric Cohort Study

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

30

estimated

Study population

Oncology

Key I/E criterion

—

Primary endpoint

•Radiological changes in pancreatic cyst characteristic as described in

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07014709
Org study IDIPMN-GLP1RA

Timeline

Milestones

Study start2025-05-31estimated
Study first posted2025-06-11actual
Last update posted2025-06-11actual
Primary completion2026-10-31estimated
Study completion2026-10-31estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Oncology

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodNon probability sample

Study population text

The study population consists of adult patients diagnosed with intraductal papillary mucinous neoplasms (IPMNs) who have been treated with GLP-1 receptor agonists (GLP-1 RAs) for diabetes or obesity management

Inclusion criteria

•> 18 years old
•Radiological diagnosis of IPMN
•Treated with GLP-1 RAs.
•Patients must have provided prior informed consent for the use of their coded clinical data in research.

Exclusion criteria

•radiological diagnosis of IPMN is unclear,
•no documented history of GLP-1 RAs use
•patients did not provide signed informed consent, or have documented refusal for research.

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
6
Safety / tolerability / PK
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Incidence of acute pancreatitis

Time frame:during the GLP1 RA treatment

Pancreatitis

event count, event

Other clinical outcomes

6 endpoints
Primary/protocol endpoint

Radiological changes in pancreatic cyst characteristic as described in the Kyoto 2023 Consensus

Time frame:during the GLP1 RA treatment

descriptive

Secondary/protocol endpoint/low confidence

Changes in serum tumor markers, CA19-9 and CEA levels

Time frame:during the GLP1 RA treatment

change from baseline, descriptive

Secondary/protocol endpoint

Changes in Endoscopic ultrasonography (EUS) characteristics

Time frame:during the GLP1 RA treatment

change from baseline, improvement

Secondary/protocol endpoint

Progression of IPMNs to high-grade dysplasia or invasive malignancy in histopathological analysis

Time frame:during the GLP1 RA treatment

categorical status, event

Secondary/protocol endpoint/low confidence

Need for surgical intervention

Time frame:during the GLP1 RA treatment

event count, event

Secondary/protocol endpoint/low confidence

Changes in IPMN surveillance protocols

Time frame:during the GLP1 RA treatment

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.